
RayzeBio Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from RayzeBio Inc
Access all reports
RayzeBio Inc is a biotechnology firm concentrated on developing radiopharmaceutical therapeutics (RPT) for cancer treatment. Their leading drug candidate, RYZ101, is in clinical trials aimed at treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Additionally, RayzeBio is working on RYZ801, a novel proprietary peptide targeting GPC3 for the treatment of hepatocellular carcinoma (HCC), among other innovative drug candidates targeting various cancers. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
RYZB
Country
🇺🇸 United States